#22Health Care· Health Care Equipment

RMDHold

ResMed

$201.88USD

Composite Score65.8Strong

<−99

Margin of safety<−99%Expensive

Fair value$97.65

Target$287.16

Loss chance53%

Price (1y)

Loading price history…

Fair price check

6 different valuation methods each estimate what RMD should be worth, then we compare to today's price.

Heavily overvalued

Models suggest RMD is far above estimated fair value

Today's price

$201.88

Median fair price

$97.65

-52% vs today

Of 5 methods:2 say cheap3 say pricey(1 outlier excluded)

P/E multiplesUndervalued
thinks it's a bargain — estimates $287.16, about 42% above today
EV/EBITDAUndervalued
thinks it's a bargain — estimates $264.12, about 31% above today
P/B multiplesOvervalued
thinks it's expensive — estimates $130.13, about 36% below today
DCF (2-stage)Overvalued
thinks it's expensive — estimates $65.16, about 68% below today
Graham (defensive)Overvalued
thinks it's expensive — estimates $62.78, about 69% below today
Residual IncomeOutlier
estimate looks unreliable — estimates $39.26 — likely unreliable

How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.

Fair price ensemble

Median fair

$97.65

Margin of safety

< −99%

Max (ex-outliers)

$287.16

Tangible BVPS

$23.33

Method	Value
Graham (defensive)	$62.78
P/E multiples(vs sub industry peers)	$287.16
P/B multiples(vs sub industry peers)	$130.13
EV/EBITDA(vs sub industry peers)	$264.12
Residual Income	$39.26
DCF (2-stage)	$65.16

extreme rim estimate
restatement history

Median of all applicable methods (current price $201.88). Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.

Pillar breakdown

8 dimensions, each scored 0–100 against the universe

Health Care median (n=59)

Quality
Profit margins & asset efficiency
81
Strong
Value
Price vs fundamentals
60
Decent
Growth
Revenue & earnings trajectory
85
Strong
Momentum
Recent price strength
22
Poor
Health
Balance sheet & solvency
82
Strong
Profitability
ROE, ROA, ROIC
76
Strong
Technical
Trend & volatility signals
46
Weak
Risk
Volatility & drawdown profile
35
Weak

0305070100

Strong (70+)Decent (50–70)Weak (30–50)Poor (<30)

Pillars not shown: Sentiment, ML (Phase 5+).

Raw fundamentals (SEC EDGAR)

Metric	Value
Market cap	$29.28B
Revenue (TTM)	$5.54B
Net income (TTM)	$1.52B
Operating cash flow (TTM)	$1.89B
CapEx (TTM)	$135.74M
Free cash flow (TTM)CFO − CapEx	$1.75B
Total assets	$8.78B
Total liabilities	$2.29B
Stockholders' equity	$6.49B
Cash & equivalents	$1.66B
Shares outstanding	145.06M
EPS (basic)	$7.82
EPS (diluted)	$7.79
P/E ratio (TTM)	19.27

TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).

Data quality

Latest filed date: 2026-05-01
Latest period end: 2026-04-27
Filing lag: 15 days
Missing metrics: 1(interest_expense)

Phase 3c — composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars land in Phases 5-6; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.